Symbols

GRDN

Guardian Pharmacy·NYSE

--(--)

GRDN fundamentals

GRDN Q4 2025 Earnings

Guardian Pharmacy (GRDN) released its earnings on Mar 11, 2026: revenue was 397.62M (YoY +17.44%), beat estimates; EPS was 0.37 (YoY +94.74%), beat estimates.

Revenue / YoY

397.62M

+17.44%

EPS / YoY

0.37

+94.74%

Report date

Mar 11, 2026

GRDN Earnings Call Summary for Q4,2025

Record 2025 Performance: 13% organic revenue growth, 27% EBITDA expansion to $115 million, and 7.9% margin. Vaccines drove $56M resident savings and 120K scripts.
2026 Outlook: EBITDA guidance raised to $120-$124M, reflecting 8.6% margin target. IRA mitigation strategies in place, with $65M 2027 branded drug headwind.
Operational Excellence: 21.5% gross margin in Q4, 60% cash conversion rate, and 90 basis point margin drag from greenfield investments.
Strategic Growth: Active M&A pipeline, 4Q acquisitions onboarding national accounts faster, and 90%+ generic script mix driving margin balance.

Earnings

EPS

Revenue

Revenue & Expenses

GRDN has released its 2025 Q4 earnings report, with revenue of 397.62M, reflecting a YoY change of 17.44%, and net profit of 21.27M, showing a YoY change of 79.59%. The Sankey diagram below clearly presents GRDN's revenue sources and cost distribution.

Key Indicators

Guardian Pharmacy (GRDN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Guardian Pharmacy (GRDN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Guardian Pharmacy (GRDN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Guardian Pharmacy (GRDN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown